The possibility of avoiding potentially costly TSC consequences, such as resection surgery for SEGA or epilepsy, cerebral shunt placement, and AML-associated renal bleeding following everolimus may balance favorably against the unwanted treatment effects of mTOR inhibitors, and everolimus may emerge as a cost-effective treatment option. The gene discussed is MTOR; the disease is acute myeloid leukemia.